Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration

Inclusion Criteria: * Male or female participants between 30 and 75 years of age, diagnosed of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume from 10 ml to 60 ml calculated by ABC/2 formula. * Within 5 days from onset to operation, and no improvement. * Glasgow Coma Scale (GCS) score of 9 to 15. * With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength≤grade 3. * Modified Rankin scale (mRS) score≤1 in past medical history. * Women of reproductive age have negative pregnancy tests. * The participants or the legal guardian/representative who are suitable and willing to participate in the clinical trial and can cooperate to complete the follow-ups. Exclusion Criteria: * Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation AVM and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage. * In the sequela stage of cerebral trauma. * Hematoma involves other structures including but not limited to the thalamus and midbrain or complicated with intraventricular hemorrhage. * With neurologic impairment before cerebral hemorrhage onset. * Participants receiving anticoagulant or antiplatelet therapy. * The disease progresses quickly. Manifestation of cerebral herniation such as bilateral dilated pupil, disappearance of light reflex, and unstable vital signs. * Active stage of infectious diseases including but not limited to HIV, hepatitis B, and C. * History of poorly controlled seizures. * History of severe co-morbidity (including but not limited to hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment. Coagulation dysfunction INR \>1.4, PTT\>37 seconds, thrombocytopenia (PLT\<8×10\^9/L), serum creatinine exceeded the upper limit of normal by 1.4 times, serum ALT \>150U/L, and/or serum total bilirubin \>1.6mg/dl. * Participants with a mechanical heart valve. Biological valves are acceptable. * Participants with a risk of embolism (including but not limited to a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable. * May be pregnant in the near future or already pregnant. * Enrolled in this clinical trial or participating in other interventional medical research or clinical trials at the same time. * Participants difficult to follow up or with poor compliance due to various reasons (including but not limited to geographical and social factors, drug or alcohol abuse). * Participants or the legal guardian/representative is unable or unwilling to give the written informed consent. * Vulnerable groups (including but not limited to mental retardation, abuse, inability to fully exercise informed consent). * Any subject that the researchers think is not suitable for enrollment.